WASHINGTON – Data from the Heracles and SUMMIT trials presented at the 2017 annual meeting of the American Association for Cancer Research confirmed that HER2-targeting drugs, which were originally developed for breast cancer, can be useful both for treating other tumor types and for patients whose HER2 gene is mutated but who do not overexpress HER2 protein.